

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re Patent Application of BOTTAZZI et al.
Serial No. 09/555,473
Filed: May 31, 2000
Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN PTX3
Assistant Commissioner for Patents
Washington, DC 20231
Atty Dkt. 2801-18
C# M#
Group Art Unit: 1632
Examiner: Dhruva
Date: September 14, 2001

1632
#10
RECEIVED
SEP 18 2001
TECH CENTER 1600/2900

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 80.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) \$ 110.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) \$ 0.00
☐ Please enter the previously unentered, filed
☐ Submission attached

Subtotal \$ 110.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00
☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 110.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:eaw

NIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

09/17/2001 TBESHAH1 00000070 09555473

01 FC:115

110.00 OP

RECEIVED

SEP 18 2001

TECH CENTER 1600/290

#11

Bp

9-18-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BOTTAZZI et al.

Serial No. 09/555,473

Filed: May 31, 2000

For: **PHARMACEUTICAL COMPOSITIONS CONTAINING THE
LONG PENTRAXIN PTX3**



Atty. Ref.: 2801-18

Group: 1632

Examiner: Dhruva

September 14, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE

Responsive to the Official Action dated June 5, 2001, the applicants elect, with traverse, the subject matter of Group I for further prosecution in the above. Withdrawal of the restriction requirement is requested as examination of all of the claimed subject matter would not be an undue burden on the Examiner. The period for responding to the Office Action of June 5, 2001, has been extended up to and including October 5, 2001, by submission of the requisite petition and fee, attached.


Withdrawal of the restriction requirement and an early and favorable Action on all of the claimed subject matter are requested.

BOTTAZZI et al.
Serial No. 09/555,473

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

BJS:eaw
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100